Article Information
History
- February 12, 2021.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available for use under a CC0 license.
Author Information
- Andrew D Redd1,2,#,
- Alessandra Nardin3,
- Hassen Kared3,
- Evan M Bloch4,
- Andrew Pekosz5,
- Oliver Laeyendecker1,2,
- Brian Abel3,
- Michael Fehlings3,
- Thomas C Quinn1,2 and
- Aaron AR Tobian4
- 1Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA
- 2Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA
- 3ImmunoScape Pte Ltd, Singapore
- 4Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA
- 5Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
- ↵#Corresponding author: Andrew D. Redd, Rangos 540, 851 N Wolfe St, Baltimore MD, 21205, aredd2{at}jhmi.edu; 410-614-0813
Posted February 12, 2021.
CD8+ T cell responses in COVID-19 convalescent individuals target conserved epitopes from multiple prominent SARS-CoV-2 circulating variants
